共 80 条
- [1] Siegel RL(2021)Cancer statistics, 2021 CA Cancer J Clin 71 7-33
- [2] Miller KD(2018)The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma Cell Rep 23 313-326
- [3] Fuchs HE(2021)Update on first-line combination treatment approaches in metastatic clear-cell renal cell carcinoma Curr Treat Options Oncol 22 15-49
- [4] Jemal A(2021)A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma J Clin Pharm Ther 46 35-896
- [5] Ricketts CJ(2007)Sunitinib: from rational design to clinical efficacy J Clin Oncol 25 884-124
- [6] De Cubas AA(2007)Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115-3590
- [7] Fan H(2009)Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 3584-2308
- [8] Christensen BR(2011)Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth Mol Cancer Ther 10 2298-597
- [9] Hajja YM(2017)Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN Trial J Clin Oncol 35 591-1813
- [10] Koshkin V(2015)Nivolumab versus everolimus in advanced renal-cell carcinoma N Engl J Med 373 1803-841